|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Govindan R, Page N, Morgensztern D, Read
W, Tierney R, Vlahiotis A, Spitznagel EL and Piccirillo J: Changing
epidemiology of small-cell lung cancer in the United States over
the last 30 years: Analysis of the surveillance, epidemiologic, and
end results database. J Clin Oncol. 24:4539–4544. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Barlesi F, Mazieres J, Merlio JP,
Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I,
Westeel V, et al: Routine molecular profiling of patients with
advanced non-small-cell lung cancer: Results of a 1-year nationwide
programme of the French cooperative thoracic intergroup (IFCT).
Lancet. 387:1415–1426. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rodríguez M, Ajona D, Seijo LM, Sanz J,
Valencia K, Corral J, Mesa-Guzmán M, Pío R, Calvo A, Lozano MD, et
al: Molecular biomarkers in early stage lung cancer. Transl Lung
Cancer Res. 10:1165–1185. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Reck M, Rodriguez-Abreu D, Robinson A, Hui
R, Csoszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et
al: Updated analysis of KEYNOTE-024: Pembrolizumab versus
platinum-based chemotherapy for advanced non-small-cell lung cancer
with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol.
37:537–546. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Johung KL, Yeh N, Desai NB, Williams TM,
Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg
S, et al: Extended survival and prognostic factors for patients
with ALK-rearranged non-small-cell lung cancer and brain
metastasis. J Clin Oncol. 34:123–129. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Crinò L, Kim D, Riely GJ, Janne PA,
Blackhall FH, Hirsh DRC, Mok T, Solomon JB, Park K, Gadgeel SM, et
al: Initial phase II results with crizotinib in advanced
ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J
Clin Oncol. 29 (Suppl 15)(S7514)2011.
|
|
10
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Solomon BJ, Kim DW, Wu YL, Nakagawa K,
Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, et al:
Final overall survival analysis from a study comparing first-line
crizotinib versus chemotherapy in ALK-mutation-positive
non-small-cell lung cancer. J Clin Oncol. 36:2251–2258.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dagogo-Jack I and Shaw AT: Crizotinib
resistance: Implications for therapeutic strategies. Ann Oncol. 27
(Suppl 3):iii42–iii50. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474.
2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Conde E, Rojo F, Gómez J, Enguita AB,
Abdulkader I, González A, Lozano D, Mancheño N, Salas C, Salido M,
et al: Molecular diagnosis in non-small-cell lung cancer: Expert
opinion on ALK and ROS1 testing. J Clin Pathol. 75:145–153.
2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sheikine Y, Rangachari D, McDonald DC,
Huberman MS, Folch ES, VanderLaan PA and Costa DB: EGFR testing in
advanced non-small-cell lung cancer, a mini-review. Clin Lung
Cancer. 17:483–492. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ricciuti B, De Giglio A, Mecca C, Arcuri
C, Marini S, Metro G, Baglivo S, Sidoni A, Bellezza G, Crinò L and
Chiari R: Precision medicine against ALK-positive non-small cell
lung cancer: Beyond crizotinib. Med Oncol. 35(72)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rangachari D, Le X, Shea M, Huberman MS,
VanderLaan PA, Kobayashi SS and Costa DB: Cases of ALK-rearranged
lung cancer with 5-year progression-free survival with crizotinib
as initial precision therapy. J Thorac Oncol. 12:e175–e177.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kosaka T, Yajima T, Yamaki E, Nakazawa S,
Tomizawa K, Onozato R, Yamazaki A, Hirato J, Yatabe Y, Shimizu K,
et al: Long-term complete response in a patient with postoperative
recurrent ALK-rearranged lung adenocarcinoma treated with
crizotinib: A case report. Mol Clin Oncol. 11:309–312.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gulmez A Dr: Prolonged survival without
progression under crizotinib treatment. Cancer Treat Res Commun.
25(100259)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nakagawa K, Hida T, Nokihara H, Morise M,
Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, et al:
Final progression-free survival results from the J-ALEX study of
alectinib versus crizotinib in ALK-positive non-small-cell lung
cancer. Lung Cancer. 139:195–19. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Nishio M, Kim DW, Wu YL, Nakagawa K,
Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, et
al: Crizotinib versus chemotherapy in Asian patients with
ALK-positive advanced non-small cell lung cancer. Cancer Res Treat.
50:691–700. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mok T, Camidge DR, Gadgeel SM, Rosell R,
Dziadziuszko R, Kim DW, Pérol M, Ou SI, Ahn JS, Shaw AT, et al:
Updated overall survival and final progression-free survival data
for patients with treatment-naive advanced ALK-positive
non-small-cell lung cancer in the ALEX study. Ann Oncol.
31:1056–1064. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lei Y, Lei Y, Shi X and Wang J: EML4-ALK
fusion gene in non-small cell lung cancer. Oncol Lett.
24(277)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Pan Y, Deng C, Qiu Z, Cao C and Wu F: The
resistance mechanisms and treatment strategies for ALK-rearranged
non-small cell lung cancer. Front Oncol. 11(713530)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yoshida T, Oya Y, Tanaka K, Shimizu J,
Horio Y, Kuroda H, Sakao Y, Hida T and Yatabe Y: Differential
crizotinib response duration among ALK fusion variants in
ALK-positive non-small-cell lung cancer. J Clin Oncol.
34:3383–3389. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Woo CG, Seo S, Kim SW, Jang SJ, Park KS,
Song JY, Lee B, Richards MW, Bayliss R, Lee DH and Choi J:
Differential protein stability and clinical responses ofEML4-ALK
fusion variants to various ALK inhibitors in advancedALK-rearranged
non-small cell lung cancer. Ann Oncol. 28:791–797. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock
AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, et al:
Impact of EML4-ALK variant on resistance mechanisms and clinical
outcomes in ALK-positive lung cancer. J Clin Oncol. 36:1199–1206.
2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lei YY, Yang JJ, Zhang XC, Zhong WZ, Zhou
Q, Tu HY, Tian HX, Guo WB, Yang LL, Yan HH, et al: Anaplastic
lymphoma kinase variants and the percentage of ALK-positive tumor
cells and the efficacy of crizotinib in advanced NSCLC. Clin Lung
Cancer. 17:223–231. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Cha YJ, Kim HR and Shim HS: Clinical
outcomes in ALK-rearranged lung adenocarcinomas according to ALK
fusion variants. J Transl Med. 14(296)2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li Y, Zhang T, Zhang J, Li W, Yuan P, Xing
P, Zhang Z, Chuai S, Li J and Ying J: Response to crizotinib in
advanced ALK-rearranged non-small cell lung cancers with different
ALK-fusion variants. Lung Cancer. 118:128–133. 2018.PubMed/NCBI View Article : Google Scholar
|
